Physician profile
Ann Mary Roy
NPI 1922675537
$4,484.14
in general payments reported to CMS, 2019-2025
21 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $996 · 2023: $48.02 · 2024: $1,137 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,047.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $820.88 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $516.03 | 2021-2022 | |
| Novo Nordisk INC | $473.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $442.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $367.91 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $279.96 | 2024-2025 | Gemtesa, Myfembree |
| Merck Sharp & Dohme LLC | $248.54 | 2024-2025 | Verquvo, Capvaxive |
| Abbvie INC. | $237.57 | 2022-2024 | |
| Lilly USA, LLC | $235.56 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $173.55 | 2024 | Inpefa |
| Corcept Therapeutics | $156.20 | 2024-2025 | Korlym |
| Intra-Sana Laboratories | $115.06 | 2022 | |
| Glaxosmithkline, LLC. | $104.91 | 2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $78.69 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.95 | 2024-2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.75 | 2024 | Evenity, Prolia |
| Intercept Pharmaceuticals, INC. | $47.56 | 2021-2022 | |
| Cequr Corporation | $35.12 | 2025 | Cequr Simplicity |
| Radius Health, INC. | $19.27 | 2025 | Tymlos |
| Exeltis, USA INC. | $16.29 | 2024 | Slynd |
| Exact Sciences Corporation | $14.05 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.